Cetera Investment Advisers cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 58,115 shares of the medical research company's stock after selling 2,078 shares during the period. Cetera Investment Advisers' holdings in Thermo Fisher Scientific were worth $30,233,000 at the end of the most recent quarter.
Several other hedge funds have also added to or reduced their stakes in TMO. Cypress Advisory Group LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $253,000. Nordea Investment Management AB lifted its holdings in shares of Thermo Fisher Scientific by 23.6% in the fourth quarter. Nordea Investment Management AB now owns 55,452 shares of the medical research company's stock worth $28,868,000 after buying an additional 10,606 shares in the last quarter. S.E.E.D. Planning Group LLC raised its stake in Thermo Fisher Scientific by 6.2% in the fourth quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock valued at $5,528,000 after purchasing an additional 618 shares in the last quarter. Czech National Bank grew its position in Thermo Fisher Scientific by 6.6% during the fourth quarter. Czech National Bank now owns 82,934 shares of the medical research company's stock valued at $43,145,000 after acquiring an additional 5,118 shares during the last quarter. Finally, Douglas Lane & Associates LLC grew its position in Thermo Fisher Scientific by 1.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 182,511 shares of the medical research company's stock valued at $94,948,000 after acquiring an additional 3,460 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
TMO has been the subject of several recent analyst reports. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. StockNews.com cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Friday, April 25th. Royal Bank of Canada decreased their price objective on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research report on Thursday, April 10th. Five equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $607.43.
Read Our Latest Analysis on TMO
Insider Buying and Selling
In related news, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares of the company's stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,075 shares of company stock valued at $7,305,942. 0.33% of the stock is currently owned by company insiders.
Thermo Fisher Scientific Stock Performance
Shares of NYSE TMO traded up $29.03 during trading hours on Monday, reaching $432.16. The stock had a trading volume of 3,707,241 shares, compared to its average volume of 1,807,192. The firm has a 50-day moving average of $464.67 and a 200-day moving average of $514.56. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The firm has a market cap of $163.14 billion, a price-to-earnings ratio of 26.14, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a fifty-two week low of $401.75 and a fifty-two week high of $627.88.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company's revenue for the quarter was up .2% on a year-over-year basis. During the same period in the prior year, the business posted $5.11 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.
Thermo Fisher Scientific Increases Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were issued a dividend of $0.43 per share. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.
Thermo Fisher Scientific Company Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
